Previous 10 | Next 10 |
CureVac (CVAC) -47% as Bill Gates-backed biotech shows below-par efficacy for COVID-19 vaccine candidate.Gaucho Group (VINO) -20%.Creatd (CRTD) -17% after proposing stock offeringNovan (NOVN) -14% after proposing capital raise.Torchlight Energy Resources (TRCH)...
3 Top Biotech Penny Stocks to Watch in 2021 Making a list of biotech penny stocks to watch is easy in 2021. With the pandemic putting a major emphasis on the biotech industry as a whole, corresponding penny stocks have jumped tremendously in value during the past year and a half. Wh...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aprea Therapeutics (NASDAQ: APRE ) stock is seeing major gains on Wednesday after revealing results from a recent Phase 1/2 trial for eprenetapopt, venetoclax, and azacitidine. Source: Bukhta Yurii / Shutterstock.c...
Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%,...
37% CR rate in 30 efficacy-evaluable patients BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, to...
BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Greg Korbel, Senior Vice President and...
BOSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chie...
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three mon...
BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that it will host a virtual R&D D...
Aprea Therapeutics Inc. (NASDAQ:APRE) traded at a new 52-week low today of $4.31. So far today approximately 1.9 million shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Aprea Therapeutics Inc. has traded in a range of $4.31 t...
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NASDAQ Market:
Aprea Therapeutics Inc. Website:
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represent...
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been fo...